Now, in its 25th year, the Restylane portfolio continues to grow and expand.

Galderma’s Restylane is  celebrating 25 years on the market.

Since launching in Europe in 1996, Restylane has celebrated many milestones across the globe. This includes the first approval for use by the U.S. Food and Drug Administration (FDA) in 2003 and in China by the National Medical Products Administration (NMPA), (Formerly China Food and Drug Administration or CFDA) in 2008.

Now, in its 25th year, the Restylane portfolio continues to grow and expand. Earlier this month, Restylane Eyelight launched as a targeted treatment solution to combat under-eye shadows. In February 2021, the FDA approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21.

The Restylane portfolio comprises two complementary gel technologies, the non-animal stabilized hyaluronic acid (NASHA) process and Optimal Balance Technology (OBT) for personalized, natural-looking results. 

 “The depth of experience from Restylane over the last 25 years has enabled us to build upon our expertise to innovate and develop new formulations and treatments. With over 30 ongoing pipeline projects in aesthetics alone, we will continue to enhance our diverse and broad portfolio of sophisticated brands to advance dermatology for every skin story,  says Flemming Ørnskov, M.D., MPH, the CEO of Galderma.